JP6125034B2 - トリアジンを用いた新規処置 - Google Patents
トリアジンを用いた新規処置 Download PDFInfo
- Publication number
- JP6125034B2 JP6125034B2 JP2015546022A JP2015546022A JP6125034B2 JP 6125034 B2 JP6125034 B2 JP 6125034B2 JP 2015546022 A JP2015546022 A JP 2015546022A JP 2015546022 A JP2015546022 A JP 2015546022A JP 6125034 B2 JP6125034 B2 JP 6125034B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- human animal
- triazine
- composition according
- intramuscular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 title description 43
- 238000011282 treatment Methods 0.000 title description 29
- 239000000203 mixture Substances 0.000 claims description 64
- 238000010255 intramuscular injection Methods 0.000 claims description 40
- 239000007927 intramuscular injection Substances 0.000 claims description 40
- 230000037396 body weight Effects 0.000 claims description 36
- 208000015181 infectious disease Diseases 0.000 claims description 21
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 18
- 238000010254 subcutaneous injection Methods 0.000 claims description 18
- 239000007929 subcutaneous injection Substances 0.000 claims description 18
- 238000002347 injection Methods 0.000 claims description 17
- 239000007924 injection Substances 0.000 claims description 17
- 238000011321 prophylaxis Methods 0.000 claims description 13
- 241000283690 Bos taurus Species 0.000 claims description 12
- 239000000725 suspension Substances 0.000 claims description 12
- 241000271566 Aves Species 0.000 claims description 11
- 239000013543 active substance Substances 0.000 claims description 11
- 210000003205 muscle Anatomy 0.000 claims description 11
- 206010023076 Isosporiasis Diseases 0.000 claims description 10
- 241001494479 Pecora Species 0.000 claims description 10
- 150000004698 iron complex Chemical class 0.000 claims description 10
- 208000003495 Coccidiosis Diseases 0.000 claims description 9
- 241000282887 Suidae Species 0.000 claims description 9
- 229910052742 iron Inorganic materials 0.000 claims description 9
- 210000001562 sternum Anatomy 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 8
- 241000282472 Canis lupus familiaris Species 0.000 claims description 7
- 239000003242 anti bacterial agent Substances 0.000 claims description 7
- 241000282326 Felis catus Species 0.000 claims description 6
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 6
- 239000011707 mineral Substances 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 230000000507 anthelmentic effect Effects 0.000 claims description 5
- 239000000921 anthelmintic agent Substances 0.000 claims description 5
- 229940124339 anthelmintic agent Drugs 0.000 claims description 5
- OCINXEZVIIVXFU-UHFFFAOYSA-N 1-methyl-3-[3-methyl-4-[4-(trifluoromethylthio)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(SC(F)(F)F)C=C1 OCINXEZVIIVXFU-UHFFFAOYSA-N 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 229960000898 toltrazuril Drugs 0.000 claims description 3
- 206010037075 Protozoal infections Diseases 0.000 claims description 2
- 229910021519 iron(III) oxide-hydroxide Inorganic materials 0.000 claims description 2
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 claims description 2
- 244000309466 calf Species 0.000 claims 1
- 238000000034 method Methods 0.000 description 26
- 230000002265 prevention Effects 0.000 description 20
- 201000010099 disease Diseases 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 16
- 150000003918 triazines Chemical class 0.000 description 14
- -1 triazine compound Chemical class 0.000 description 12
- 208000035473 Communicable disease Diseases 0.000 description 10
- 238000007918 intramuscular administration Methods 0.000 description 9
- 239000000460 chlorine Chemical group 0.000 description 8
- 241000894007 species Species 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000002518 antifoaming agent Substances 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- XQKYUBTUOHHNDV-UHFFFAOYSA-N 2-[2,6-dichloro-4-(3,5-dioxo-1,2,4-triazin-2-yl)phenyl]-2-(4-fluorophenyl)acetonitrile Chemical compound C1=CC(F)=CC=C1C(C#N)C1=C(Cl)C=C(N2C(NC(=O)C=N2)=O)C=C1Cl XQKYUBTUOHHNDV-UHFFFAOYSA-N 0.000 description 3
- SSPYSWLZOPCOLO-UHFFFAOYSA-N 6-azauracil Chemical class O=C1C=NNC(=O)N1 SSPYSWLZOPCOLO-UHFFFAOYSA-N 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 201000008680 babesiosis Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- NFJRQODDTXZEBV-MXIFXDQUSA-M gleptoferron Chemical compound [Fe].[O-]O.OC[C@H]1O[C@H](OCC(O)C(O)C(O)C(O)C(O)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O NFJRQODDTXZEBV-MXIFXDQUSA-M 0.000 description 3
- ZFSLODLOARCGLH-UHFFFAOYSA-N isocyanuric acid Chemical compound OC1=NC(O)=NC(O)=N1 ZFSLODLOARCGLH-UHFFFAOYSA-N 0.000 description 3
- 229950005045 letrazuril Drugs 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 150000003457 sulfones Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000000230 African Trypanosomiasis Diseases 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 241000224482 Apicomplexa Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000223836 Babesia Species 0.000 description 2
- 241001235572 Balantioides coli Species 0.000 description 2
- 241000223782 Ciliophora Species 0.000 description 2
- 241000223935 Cryptosporidium Species 0.000 description 2
- 241000209630 Cystoisospora suis Species 0.000 description 2
- 241000223924 Eimeria Species 0.000 description 2
- 241000886136 Eimeria scabra Species 0.000 description 2
- 241001133637 Entamoeba suis Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000243190 Microsporidia Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 241000233872 Pneumocystis carinii Species 0.000 description 2
- 241000224003 Sarcocystis Species 0.000 description 2
- 241000223996 Toxoplasma Species 0.000 description 2
- 201000005485 Toxoplasmosis Diseases 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 208000007456 balantidiasis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- RKISUIUJZGSLEV-UHFFFAOYSA-N n-[2-(octadecanoylamino)ethyl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCNC(=O)CCCCCCCCCCCCCCCCC RKISUIUJZGSLEV-UHFFFAOYSA-N 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- BFGQTWYXWNCTSX-UHFFFAOYSA-N triazine-4,5-dione Chemical compound O=C1C=NN=NC1=O BFGQTWYXWNCTSX-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 210000002268 wool Anatomy 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- 241000224424 Acanthamoeba sp. Species 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 241001056488 Anatis Species 0.000 description 1
- 241000223846 Babesia canis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700112 Chinchilla Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 241000205707 Cystoisospora belli Species 0.000 description 1
- 241000283014 Dama Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241001098070 Echinorhynchus truttae Species 0.000 description 1
- 241000223931 Eimeria acervulina Species 0.000 description 1
- 241000289819 Eimeria adenoeides Species 0.000 description 1
- 241000994379 Eimeria anseris Species 0.000 description 1
- 241001043461 Eimeria arloingi Species 0.000 description 1
- 241001218115 Eimeria auburnensis Species 0.000 description 1
- 241000499566 Eimeria brunetti Species 0.000 description 1
- 241000646177 Eimeria chinchillae Species 0.000 description 1
- 241001327860 Eimeria dispersa Species 0.000 description 1
- 241001662550 Eimeria falciformis Species 0.000 description 1
- 241000013739 Eimeria faurei Species 0.000 description 1
- 241001485867 Eimeria flavescens Species 0.000 description 1
- 241001327857 Eimeria gallopavonis Species 0.000 description 1
- 244000309702 Eimeria hagani Species 0.000 description 1
- 241001485866 Eimeria intestinalis Species 0.000 description 1
- 241000221513 Eimeria irresidua Species 0.000 description 1
- 241001485852 Eimeria magna Species 0.000 description 1
- 241000223934 Eimeria maxima Species 0.000 description 1
- 241001485868 Eimeria media Species 0.000 description 1
- 241001452550 Eimeria meleagridis Species 0.000 description 1
- 241001278028 Eimeria meleagrimitis Species 0.000 description 1
- 241000179199 Eimeria mitis Species 0.000 description 1
- 241000499563 Eimeria necatrix Species 0.000 description 1
- 241001485851 Eimeria perforans Species 0.000 description 1
- 241001485850 Eimeria piriformis Species 0.000 description 1
- 241000886133 Eimeria polita Species 0.000 description 1
- 241000886137 Eimeria porci Species 0.000 description 1
- 241000499544 Eimeria praecox Species 0.000 description 1
- 241001485873 Eimeria stiedai Species 0.000 description 1
- 241000223932 Eimeria tenella Species 0.000 description 1
- 241001218082 Eimeria zuernii Species 0.000 description 1
- 244000294661 Emex spinosa Species 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 241001584862 Enterococcus canis Species 0.000 description 1
- 241000194028 Enterococcus columbae Species 0.000 description 1
- 241000011458 Epistylis Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000727360 Euglossa truncata Species 0.000 description 1
- 241000630885 Eumunida parva Species 0.000 description 1
- 241000356197 Euphorbia contorta Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 241000224492 Hartmannella Species 0.000 description 1
- 241000149124 Hepatozoon canis Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000567229 Isospora Species 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000693084 Mycoplasma ovis Species 0.000 description 1
- 241001147662 Neospora caninum Species 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 241001126829 Nosema Species 0.000 description 1
- 241000272458 Numididae Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241000021737 Pezicula sp. 1-40 Species 0.000 description 1
- 240000009188 Phyllostachys vivax Species 0.000 description 1
- 241000224017 Plasmodium berghei Species 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000223821 Plasmodium malariae Species 0.000 description 1
- 206010035501 Plasmodium malariae infection Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000282330 Procyon lotor Species 0.000 description 1
- 241000287530 Psittaciformes Species 0.000 description 1
- 241000283011 Rangifer Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000359273 Sarcocystis miescheriana Species 0.000 description 1
- 241001473628 Sarcocystis suihominis Species 0.000 description 1
- 241000271567 Struthioniformes Species 0.000 description 1
- 241000223777 Theileria Species 0.000 description 1
- 241000223779 Theileria parva Species 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 241000893962 Trichophyton equinum Species 0.000 description 1
- 241000223105 Trypanosoma brucei Species 0.000 description 1
- 241001442399 Trypanosoma brucei gambiense Species 0.000 description 1
- 241001442397 Trypanosoma brucei rhodesiense Species 0.000 description 1
- 241000223107 Trypanosoma congolense Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 241000223095 Trypanosoma evansi Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000001165 anti-coccidial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229910052801 chlorine Chemical group 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical class OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- 235000014413 iron hydroxide Nutrition 0.000 description 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
- RNRZILWYJWUQLH-UHFFFAOYSA-N iron;triazine Chemical compound [Fe].C1=CN=NN=C1 RNRZILWYJWUQLH-UHFFFAOYSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000003250 oocyst Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- KHUXNRRPPZOJPT-UHFFFAOYSA-N phenoxy radical Chemical group O=C1C=C[CH]C=C1 KHUXNRRPPZOJPT-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229940091440 uniferon Drugs 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Dispersion Chemistry (AREA)
Description
‐例えばクラズリル、ジクラズリル、レトラズリル及びスラズリル等の1,2,4‐トリアジンジオンの誘導体;又は
‐例えばトルトラズリル、トルラズリルスルホキシド、トルトラズリルスルホン(例えばポナズリル)等の1,3,5‐トリアジントリオンの誘導体。
「トリアジン」の用語は、特にコクシジウムの感染に対する活性物質の周知の分類を意味する。本発明の方法又は組成物に用いるための典型的なトリアジンは、所定の純度を有する以下の化学式A又はBの化合物であり、好ましくは少なくとも90%の純度を有する、また、その塩、エステル、ラセミ体、異性体、プロドラッグである。
R2はアルキル、アルコキシ、ハロゲン又はSO2N(CH3)2
R3はハロアルキルであり、
R4及びR5は互いに独立して水素又はCl原子であり、
R6はフッ素又は塩素である。
本発明において、処置の用語は、特に、病気に対する非ヒト動物の予防的処置を含む。病気に対する非ヒト動物の予防的処置は、非ヒト動物が病気の病原体(例えば病原菌、ウィルス、原虫、細胞等)に曝露される又は接触される前に、又はその曝露/接触の後で症状の発生の前に、又は病気の発生の早期段階において行われる処置を意味する。また、非ヒト動物の個体群に関して予防的処置の用語は、病気が特定のメンバーで検出された後に、他に広がる及び他を汚染することを制限する又は避けるために、その個体群の全てのメンバーを処置することを意味する。
本発明の重要な一態様は、筋肉内投与経路である。実施例の項で示すように、本発明は、反復注射の必要なく又は長期放出性又は徐放性剤形の必要なく、単回投与であっても、その後、処置された非ヒト動物に有効な予防効果を与える筋肉内投与トリアジンを示す。さらに、本発明は、非ヒト動物への更なる操作を課することなく、有効な処置が得られるように、筋肉内投与トリアジンが更なる筋肉内投与活性剤と組み合わせられ得ることを示す。
トリアジンの用量は、非ヒト動物の種及びトリアジンの性質に依存する。非ヒト動物の体重1kg当たり1〜60mg(mg/kg)のトリアジンといった従来の投与率が用いられ、好ましくは5〜50mg/kgであり、より好ましくは10〜30mg/kgである。
ブタ:20mg/kg(体重)/処置(好ましくは単回投与);
ウシ:15mg/kg(体重)/処置(好ましくは単回投与);
ヒツジ:20mg/kg(体重)/処置(好ましくは単回投与);
家禽:25mg/kg(体重)/処置(好ましくは単回投与)。
本発明は、非ヒト動物における感染症、好ましくは原虫病又は微生物病の処置(例えば保護、予防、遅延、緩和又は治療)に用いられ得る。本発明は、血液及び組織の原虫病(バベシア症、肉胞子虫症又はトキソプラズマ病等)、又は消化管の原虫病(コクシジウム病等)の処置に特に適する。
(プロトコール)
この標的動物の安全性及び有効性研究を、コクシジウム病の周知の歴史を有する農場で行った。その主な目的は、トルトラズリルの筋肉内注射の安全性及び有効性を標準的な経口投与と比較して試験することである。
グループ1:3日齢の8匹の子ブタにSD0において、トルトラズリルの単回筋肉内注射を行った(用量=20mg/kg(体重)で0.4mL/kg(体重))。
グループ2:3日齢の8匹の子ブタにSD0において、トルトラズリルの単回筋肉内注射を行った(用量=60mg/kg(体重)で1.2mL/kg(体重))。
グループ3:3日齢の8匹の子ブタにSD0において、トルトラズリルとしてのCevazurilの標準的な販売剤形を経口投与した(用量=トルトラズリルが20mg/kg(体重)で0.4mL/kg(体重))。
グループ4:3日齢の12匹の子ブタに対して処置をしなかった。
局所的及び全体的耐性、並びに体重増加について評価した。その結果は図1及び図2に示され、以下のように要約される。
‐60mg/kgまでの筋肉内注射の用量では良好な耐性が認められる。
‐痛みは無く、1.2mL/kg(体重)で注射された数匹の子ブタにおいて限定的な局所反応(浮腫)が見られたが、注射後1週間以内で消失した。
‐処置された子ブタにおいて、体重増加は正常であった。
‐筋肉内注射された子ブタは、処置されていないコントロールの子ブタよりも重くなった(SD0+29日で+2kg)。
(プロトコール)
グループ1:2日齢の10匹の子ブタにSD0において、トルトラズリルC629の単回筋肉内注射を行った(用量=トルトラズリルが20mg/kg(体重)で0.4mL/kg(体重))。
グループ2:2日齢の11匹の子ブタにSD0において、トルトラズリルC629の単回筋肉内注射を行った(用量=トルトラズリルが40mg/kg(体重)で0.8mL/kg(体重))。
グループ3:2日齢の9匹の子ブタにSD0において、トルトラズリルとしてCevazurilの標準的な販売剤形を経口投与した(用量=トルトラズリルが20mg/kg(体重)で0.4mL/kg(体重))。
グループ4:8匹の子ブタに対して処置をしなかった。
・局所的及び全体的耐性(グループ1及び2)
・下痢の発生及び糞便の硬さ
・体重増加
・グループ1、2及び3におけるトルトラズリル及びその代謝物のトルトラズリルスルホンの血清濃度。
結果を図3〜5、及び以下の表1に示す。それらは以下の通り要約できる。
・全ての試験された用量において良好な耐性があった。
・処置された動物においてオーシストの***は見られず、糞便の硬さは処置された子ブタ(G1、G2及びG3)において変わらなかった。
・感染され、経口又は筋肉内で処置された動物(G1、G2及びG3)は、コントロールの動物(G4)よりも体重がより大きく増加した。
・トルトラズリルは、筋肉内投与の後に良好に吸収される。
・トルトラズリルスルホン(例えばポナズリル)の動態は、経口的に処置された動物(G3)又は筋肉内に処置された動物(G1及びG2)で統計的な差が無かった。
Claims (15)
- 非ヒト動物の感染症の予防的処置に用いられるためのトルトラズリル及び鉄剤を含む組成物であって、
筋肉内又は皮下注射により投与されるための組成物。 - 単回注射により前記非ヒト動物に投与されるための請求項1に記載の組成物。
- 非ヒト哺乳動物の首若しくは耳の後ろ、又はトリの胸骨に隣接する筋肉に筋肉内注射することにより投与されるための請求項1又は2に記載の組成物。
- 前記非ヒト動物の体重1kg当たり1mg〜60mgで投与されるためのトルトラズリルを含む請求項3に記載の組成物。
- 前記非ヒト動物の体重1kg当たり10mg〜30mgで投与されるためのトルトラズリルを含む請求項4に記載の組成物。
- 抗生物質、駆虫剤、エンデクトサイド、抗炎症剤、ビタミン、及び/又はミネラルから選択される1つ又はそれ以上の追加的活性剤を含む請求項1〜5のいずれか1項に記載の組成物。
- 前記鉄剤は、鉄複合体である請求項1〜6のいずれか1項に記載の組成物。
- 前記トルトラズリル及び鉄剤は、共に筋肉内又は皮下注射されるために同一の剤形で組み合わせられている請求項1〜7のいずれか1項に記載の組成物。
- 前記剤形は懸濁液である請求項1〜8のいずれか1項に記載の組成物。
- 前記非ヒト動物は、ブタ、ヒツジ、ウシ、イヌ、ネコ又はトリから選択される請求項1〜9のいずれか1項に記載の組成物。
- 前記非ヒト動物における原虫感染症の予防的処置に用いられるための請求項1〜10のいずれか1項に記載の組成物。
- ブタのコクシジウム病の予防的処置に用いられるための請求項1〜11のいずれか1項に記載の組成物。
- 非ヒト動物の感染症の予防的処置に用いられるための組成物であって、
1mg〜60mgのトルトラズリルと、鉄複合体とを含み懸濁液であり、前記非ヒト動物に筋肉内注射で投与されるための組成物。 - 前記鉄複合体は、β‐オキシ水酸化鉄及びデキストラングルコヘプトン酸の水性コロイド溶液である請求項7又は13に記載の組成物。
- 前記非ヒト動物は、子ブタ又は子ウシである請求項13に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12306546.8 | 2012-12-07 | ||
EP12306546.8A EP2740469A1 (en) | 2012-12-07 | 2012-12-07 | New treatments with triazines |
PCT/EP2013/075755 WO2014086958A1 (en) | 2012-12-07 | 2013-12-06 | New treatments with triazines |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016501252A JP2016501252A (ja) | 2016-01-18 |
JP6125034B2 true JP6125034B2 (ja) | 2017-05-10 |
Family
ID=47351540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015546022A Active JP6125034B2 (ja) | 2012-12-07 | 2013-12-06 | トリアジンを用いた新規処置 |
Country Status (23)
Country | Link |
---|---|
US (1) | US9877969B2 (ja) |
EP (3) | EP2740469A1 (ja) |
JP (1) | JP6125034B2 (ja) |
KR (1) | KR102253497B1 (ja) |
CN (3) | CN112370454A (ja) |
AU (1) | AU2013353982B2 (ja) |
BR (3) | BR122021005310B1 (ja) |
CA (1) | CA2892886C (ja) |
CL (1) | CL2015001563A1 (ja) |
CY (1) | CY1123190T1 (ja) |
DK (1) | DK2928454T3 (ja) |
ES (1) | ES2778950T3 (ja) |
FR (1) | FR20C1044I2 (ja) |
HR (1) | HRP20200630T1 (ja) |
HU (2) | HUE049950T2 (ja) |
MX (1) | MX2015007128A (ja) |
NL (1) | NL301064I2 (ja) |
PH (1) | PH12015501220A1 (ja) |
PL (1) | PL2928454T3 (ja) |
PT (1) | PT2928454T (ja) |
RU (1) | RU2696265C2 (ja) |
SI (1) | SI2928454T1 (ja) |
WO (1) | WO2014086958A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007025908A1 (de) | 2007-06-01 | 2008-12-04 | Bayer Healthcare Ag | Formulierungen enthaltend Triazinone und Eisen |
EP2740469A1 (en) | 2012-12-07 | 2014-06-11 | Ceva Sante Animale | New treatments with triazines |
EP2740470A1 (en) * | 2012-12-07 | 2014-06-11 | Ceva Sante Animale | Treatment of Coccidiosis with intramuscular triazine composition |
EP2740492A1 (en) | 2012-12-07 | 2014-06-11 | Ceva Sante Animale | Triazine formulations with a second active ingredient and surfactant(s) |
EP3578182A1 (en) | 2018-06-05 | 2019-12-11 | Bayer Animal Health GmbH | Formulations containing triazinones and iron with a low amount of free iron ions |
EP3578181A1 (en) | 2018-06-05 | 2019-12-11 | Bayer Animal Health GmbH | Formulation for use in the simultaneous treatment of coccidial infections and iron deficiencies |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1183940A (en) | 1966-10-22 | 1970-03-11 | Fisons Pharmaceuticals Ltd | Ferric Hydroxide Complexes |
DE2718799A1 (de) | 1977-04-27 | 1978-11-09 | Bayer Ag | 1-(4-phenoxy-phenyl)-1,3,5-triazin- derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel und wachstumsfoerderer |
US4493826A (en) * | 1982-01-25 | 1985-01-15 | Schering Corporation | Gentamicin-gleptoferron compositions |
US5219853A (en) | 1983-01-12 | 1993-06-15 | Bayer Aktiengesellschaft | Agent for coccidiosis |
DE3300793A1 (de) | 1983-01-12 | 1984-07-12 | Bayer Ag, 5090 Leverkusen | Coccidiosemittel |
DE3516632A1 (de) | 1985-05-09 | 1986-11-13 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von 1,3,5-triazintrionen |
JPH0776524A (ja) * | 1993-07-13 | 1995-03-20 | Takeda Chem Ind Ltd | 動物用抗貧血剤 |
DE19603954C2 (de) | 1996-02-05 | 2003-04-17 | Wagon Automotive Gmbh | Prallträger für ein Kraftfahrzeug |
DE19603984A1 (de) | 1996-02-05 | 1997-08-07 | Bayer Ag | Granulate von Triazinen |
DE19824483A1 (de) | 1998-06-02 | 1999-12-09 | Bayer Ag | Halbfeste wäßrige Zubereitungen für orale Applikation von Toltrazuril-Sulfon |
CN1189175C (zh) * | 1998-10-08 | 2005-02-16 | 高新研究公司 | 用于预防和治疗原虫病的组合物和方法 |
AU4034800A (en) | 1999-10-08 | 2001-04-23 | New Ace Research Company | Novel compositions and methods for prevention and treatment of protozoal disease |
DE10040174A1 (de) * | 2000-08-17 | 2002-02-28 | Bayer Ag | Verwendung von Triazintrion-Sulfonen zur Bekämpfung von Coccidiosen |
WO2006058426A1 (en) | 2004-12-01 | 2006-06-08 | Wlt Distributors Inc. | Needle-free injector |
ES2785210T3 (es) | 2006-06-07 | 2020-10-06 | Acushot Inc | Mecanismo de carga para un inyector sin aguja |
DE102006038292A1 (de) | 2006-08-16 | 2008-02-21 | Bayer Healthcare Ag | Transdermale Anwendung von Triazinen zur Bekämpfung von Coccidien-Infektionen |
DE102007025908A1 (de) * | 2007-06-01 | 2008-12-04 | Bayer Healthcare Ag | Formulierungen enthaltend Triazinone und Eisen |
CN102112167A (zh) | 2008-03-07 | 2011-06-29 | 医用注射器公司 | 皮内注射器及其用途 |
SI22751A (sl) | 2008-04-03 | 2009-10-31 | Krka, D.D., Novo Mesto | Toltrazuril z izboljĺ animi lastnostmi za raztapljanje |
FR2946882B1 (fr) | 2009-06-18 | 2011-08-26 | Ceva Sante Animale | Suspension veterinaire gelifiee de fer |
CN101947201B (zh) | 2010-09-08 | 2011-12-28 | 洛阳惠中兽药有限公司 | 兽药纳米混悬剂及其制备方法与应用 |
CN102512366A (zh) | 2011-12-28 | 2012-06-27 | 广州市和生堂动物药业有限公司 | 妥曲珠利悬浮乳剂及其制备方法 |
CN102743334A (zh) | 2012-07-30 | 2012-10-24 | 郑州后羿制药有限公司 | 一种妥曲珠利注射剂及其制备方法 |
EP2740469A1 (en) | 2012-12-07 | 2014-06-11 | Ceva Sante Animale | New treatments with triazines |
EP2740492A1 (en) | 2012-12-07 | 2014-06-11 | Ceva Sante Animale | Triazine formulations with a second active ingredient and surfactant(s) |
EP2740470A1 (en) | 2012-12-07 | 2014-06-11 | Ceva Sante Animale | Treatment of Coccidiosis with intramuscular triazine composition |
EP3578181A1 (en) | 2018-06-05 | 2019-12-11 | Bayer Animal Health GmbH | Formulation for use in the simultaneous treatment of coccidial infections and iron deficiencies |
-
2012
- 2012-12-07 EP EP12306546.8A patent/EP2740469A1/en not_active Withdrawn
-
2013
- 2013-12-06 WO PCT/EP2013/075755 patent/WO2014086958A1/en active Application Filing
- 2013-12-06 RU RU2015127025A patent/RU2696265C2/ru active
- 2013-12-06 EP EP13802596.0A patent/EP2928454B1/en active Active
- 2013-12-06 CN CN202011031157.2A patent/CN112370454A/zh active Pending
- 2013-12-06 BR BR122021005310-3A patent/BR122021005310B1/pt active IP Right Grant
- 2013-12-06 CA CA2892886A patent/CA2892886C/en active Active
- 2013-12-06 JP JP2015546022A patent/JP6125034B2/ja active Active
- 2013-12-06 DK DK13802596.0T patent/DK2928454T3/da active
- 2013-12-06 AU AU2013353982A patent/AU2013353982B2/en active Active
- 2013-12-06 BR BR122021005311-1A patent/BR122021005311B1/pt active IP Right Grant
- 2013-12-06 HU HUE13802596A patent/HUE049950T2/hu unknown
- 2013-12-06 PL PL13802596T patent/PL2928454T3/pl unknown
- 2013-12-06 PT PT138025960T patent/PT2928454T/pt unknown
- 2013-12-06 SI SI201331711T patent/SI2928454T1/sl unknown
- 2013-12-06 MX MX2015007128A patent/MX2015007128A/es unknown
- 2013-12-06 CN CN201380063619.0A patent/CN104981233A/zh active Pending
- 2013-12-06 KR KR1020157018136A patent/KR102253497B1/ko active IP Right Grant
- 2013-12-06 BR BR112015013182A patent/BR112015013182A2/pt not_active Application Discontinuation
- 2013-12-06 CN CN202110239548.1A patent/CN113144202A/zh active Pending
- 2013-12-06 US US14/650,046 patent/US9877969B2/en active Active
- 2013-12-06 EP EP20158340.8A patent/EP3721869A1/en active Pending
- 2013-12-06 ES ES13802596T patent/ES2778950T3/es active Active
-
2015
- 2015-06-01 PH PH12015501220A patent/PH12015501220A1/en unknown
- 2015-06-05 CL CL2015001563A patent/CL2015001563A1/es unknown
-
2020
- 2020-04-15 HR HRP20200630TT patent/HRP20200630T1/hr unknown
- 2020-04-16 CY CY20201100364T patent/CY1123190T1/el unknown
- 2020-09-16 NL NL301064C patent/NL301064I2/nl unknown
- 2020-09-16 HU HUS2000037C patent/HUS2000037I1/hu unknown
- 2020-09-16 FR FR20C1044C patent/FR20C1044I2/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6125034B2 (ja) | トリアジンを用いた新規処置 | |
CA2892887C (en) | Treatment of coccidiosis with intramuscular triazine compositions | |
CA2660762C (en) | Transdermal application of triazines for controlling infections with coccidia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150928 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160412 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160707 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161004 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170321 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170404 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6125034 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |